These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29023264)

  • 1. Survival trends among patients with metastatic melanoma in the pretargeted and the post-targeted era: a US population-based study.
    Uprety D; Bista A; Chennamadhavuni A; Niroula A; Jafri SIM; Smith A; Arjyal L
    Melanoma Res; 2018 Feb; 28(1):56-60. PubMed ID: 29023264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic score for patients with advanced melanoma treated with ipilimumab.
    Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
    Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras.
    Li P; Wong YN; Armstrong K; Haas N; Subedi P; Davis-Cerone M; Doshi JA
    Cancer Med; 2016 Feb; 5(2):169-81. PubMed ID: 26645975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-Based Disparities in Metastatic Melanoma Patients Treated in the Immune Checkpoint Inhibitors (ICI)
    Safi M; Al-Azab M; Jin C; Trapani D; Baldi S; Adlat S; Wang A; Ahmad B; Al-Madani H; Shan X; Liu J
    Front Immunol; 2021; 12():609728. PubMed ID: 34887846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients.
    Shek D; Tomlinson B; Brown M; Brunson A; Pan CX; Lara PN
    Clin Genitourin Cancer; 2012 Jun; 10(2):93-8. PubMed ID: 22382008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy.
    Verver D; Grünhagen DJ; van Akkooi ACJ; Aarts MJB; van den Berkmortel FWPJ; van den Eertwegh AJM; de Groot JWB; Boers-Sonderen MJ; Haanen JBAG; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Tije AJT; Vreugdenhil G; Verhoef C; van der Veldt AAM
    Cancer Immunol Immunother; 2021 Nov; 70(11):3123-3135. PubMed ID: 33774697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
    Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
    JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study.
    Middleton MR; Dalle S; Claveau J; Mut P; Hallmeyer S; Plantin P; Highley M; Kotapati S; Le TK; Brokaw J; Abernethy AP
    Cancer Med; 2016 Jul; 5(7):1436-43. PubMed ID: 27118102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
    Schadendorf D; Hodi FS; Robert C; Weber JS; Margolin K; Hamid O; Patt D; Chen TT; Berman DM; Wolchok JD
    J Clin Oncol; 2015 Jun; 33(17):1889-94. PubMed ID: 25667295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.
    Goldman C; Tchack J; Robinson EM; Han SW; Moran U; Polsky D; Berman RS; Shapiro RL; Ott PA; Osman I; Zhong H; Pavlick AC; Wilson MA
    Oncology; 2017; 93(3):164-176. PubMed ID: 28601879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologic complete response to intralesional interleukin-2 therapy associated with improved survival in melanoma patients with in-transit disease.
    Hassan S; Petrella TM; Zhang T; Kamel-Reid S; Nordio F; Baccarelli A; Sade S; Naert K; Habeeb AA; Ghazarian D; Wright FC
    Ann Surg Oncol; 2015; 22(6):1950-8. PubMed ID: 25366584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab.
    Valpione S; Martinoli C; Fava P; Mocellin S; Campana LG; Quaglino P; Ferrucci PF; Pigozzo J; Astrua C; Testori A; Chiarion-Sileni V
    Eur J Cancer; 2015 Sep; 51(14):2086-94. PubMed ID: 26227432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term survival with modern therapeutic agents against metastatic melanoma-vemurafenib and ipilimumab in a daily life setting.
    Lang BM; Peveling-Oberhag A; Faidt D; Hötker AM; Weyer-Elberich V; Grabbe S; Loquai C
    Med Oncol; 2018 Jan; 35(3):24. PubMed ID: 29387968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival outcomes in an older US population with advanced melanoma and central nervous system metastases: SEER-Medicare analysis.
    Sadetsky N; Hernandez A; Wallick CJ; McKenna EF; Surinach A; Colburn DE
    Cancer Med; 2020 Sep; 9(17):6216-6224. PubMed ID: 32667719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of sentinel lymph node involvement in a modern, large series of desmoplastic melanoma.
    Egger ME; Huber KM; Dunki-Jacobs EM; Quillo AR; Scoggins CR; Martin RC; Stromberg AJ; McMasters KM; Callender GG
    J Am Coll Surg; 2013 Jul; 217(1):37-44; discussion 44-5. PubMed ID: 23791271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.
    Gaudy-Marqueste C; Dussouil AS; Carron R; Troin L; Malissen N; Loundou A; Monestier S; Mallet S; Richard MA; Régis JM; Grob JJ
    Eur J Cancer; 2017 Oct; 84():44-54. PubMed ID: 28783540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era.
    Lamba N; Ott PA; Iorgulescu JB
    JAMA Netw Open; 2022 Aug; 5(8):e2225459. PubMed ID: 36006646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.
    Zimmer L; Eigentler TK; Kiecker F; Simon J; Utikal J; Mohr P; Berking C; Kämpgen E; Dippel E; Stadler R; Hauschild A; Fluck M; Terheyden P; Rompel R; Loquai C; Assi Z; Garbe C; Schadendorf D
    J Transl Med; 2015 Nov; 13():351. PubMed ID: 26541511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is sex an independent prognostic factor in cutaneous head and neck melanoma?
    Arce PM; Camilon PR; Stokes WA; Nguyen SA; Lentsch EJ
    Laryngoscope; 2014 Jun; 124(6):1363-7. PubMed ID: 24122966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases.
    Patel KR; Shoukat S; Oliver DE; Chowdhary M; Rizzo M; Lawson DH; Khosa F; Liu Y; Khan MK
    Am J Clin Oncol; 2017 Oct; 40(5):444-450. PubMed ID: 26017484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.